Resveratrol is a naturally occurring polyphenol stilbene found in plant foods such as grapes and red wine, and human research has studied it most often in Diabetes and Glycemic Control, Cardiovascular Health, Liver Health, and Cognitive Health. ((Research)) ((Review))
Resveratrol is best understood in human research as an orally administered plant-derived compound with uneven direct-use evidence across cardiometabolic, liver, and cognitive domains. Human evidence consists mainly of randomized trials in specific populations, supported by multiple meta-analyses that often find mixed or small overall effects rather than consistent clinical benefit. Cardiometabolic and liver-related questions have been studied most often, while cognitive research is smaller and more heterogeneous. Overall, the literature is usable but incomplete, with important limits related to formulation, rapid metabolism, and inconsistent trial results across doses and populations. ((Review)) ((Review)) ((Review))
Ingredient Snapshot
Research Snapshot
Resveratrol is a plant-derived polyphenol whose human research profile is strongest in cardiometabolic and liver-related studies, with a smaller but notable cognitive literature. The most repeated human trial programs have examined Diabetes and Glycemic Control, Cardiovascular Health, and Liver Health, while Cognitive Health is supported by fewer and more heterogeneous randomized studies. Across these domains, pooled reviews often report mixed, small, or inconsistent effects rather than a stable pattern of broad clinical benefit. ((Review)) ((Review)) ((Review))
Typical studied human exposures range from lower repeated oral doses such as 40-75 mg/day to higher daily regimens of 500 mg/day to 2 g/day, plus single-dose pharmacokinetic studies from 25 mg to 2.5 g. A major interpretation limit is that oral absorption and clinical exposure do not track simply: resveratrol can be absorbed, but unchanged circulating resveratrol is often low because it is rapidly metabolized, and enhanced formulations can materially change exposure. Overall, the human evidence base is best described as limited to mixed direct-use evidence, with stronger pharmacokinetic rationale than consistent clinical outcome confirmation. ((Research)) ((Research)) ((Review))
A further limitation is heterogeneity across populations, dose levels, study duration, and formulation. That variation helps explain why favorable findings in some individual trials are not consistently reproduced in broader meta-analyses. ((Review)) ((Review))
Introduction
Resveratrol is a naturally occurring polyphenolic compound in the stilbene family that is found in grapes, red wine, and some other plant foods. In human research, it is usually studied as an orally administered purified compound or trans-resveratrol formulation rather than only as a food exposure. ((Research)) ((EFSA))
People usually look up resveratrol because it has been studied in areas linked to metabolic risk, vascular function, fatty liver disease, and aging-related cognition. Human research has attracted interest partly because laboratory and mechanistic work suggested broad biological activity, but clinical trials in people have produced mixed and often formulation-sensitive findings. ((Review)) ((Review))
This article is informational only, describes resveratrol as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
Human Research Findings by Condition
Diabetes and Glycemic Control
Human research on Diabetes and Glycemic Control includes multiple randomized trials, but the overall signal is mixed rather than consistently positive. Some studies report improved glucose-related measures, while systematic review evidence concludes that the clinical picture in adults with type 2 diabetes remains limited and not clearly practice-changing. ((Research)) ((Review))
Key human study
Dose studied: 800 mg/day
Population: Adults with type 2 diabetes
Duration: 8 weeks
A randomized, double-blind, placebo-controlled trial examined oral resveratrol in adults with type 2 diabetes and reported lower blood glucose after 8 weeks. However, the same study did not show clear improvement in measured inflammatory markers, which makes the result more specific to glycemic outcomes than to broader metabolic inflammation.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: ((Research))
Optional supporting context citation:
((Review))
—
Additional human study (if meaningful additional evidence exists)
Dose studied: 40 mg/day or 500 mg/day
Population: Adults with type 2 diabetes
Duration: 6 months
A randomized, double-blind, placebo-controlled trial in 192 patients with type 2 diabetes compared two daily dose levels over six months. The study did not find measurable improvement in CRP or a broader metabolic outcome pattern, which provides an important neutral contrast to smaller positive studies.
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: ((Research))
—
Cardiovascular Health
Human research in Cardiovascular Health has evaluated resveratrol mainly through vascular function and cardiometabolic risk-marker studies, with mixed results across direct trials and meta-analyses. Individual randomized trials are often neutral, while pooled analyses suggest at most modest effects in selected vascular endpoints or higher-dose subsets. ((Research)) ((Review))
Key human study
Dose studied: 75 mg twice daily
Population: Overweight and slightly obese adults
Duration: 4 weeks
A randomized, placebo-controlled crossover trial tested trans-resveratrol in adults with overweight or mild obesity and measured fasting and postprandial endothelial function. The study did not find significant changes in flow-mediated dilation or endothelial biomarkers, suggesting no clear short-term vascular benefit in this population at the tested regimen.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: ((Research))
Optional supporting context citation:
((Review))
—
Additional human study (if meaningful additional evidence exists)
Dose studied: Not clearly extractable from the locked source summary
Population: Overweight or slightly obese adults
Duration: Crossover trial duration not restated in the locked summary
A randomized, placebo-controlled crossover trial examined cardiovascular-related metabolic risk markers in overweight or slightly obese adults. The trial reported no clear effect on these markers, reinforcing the pattern that direct vascular and cardiometabolic findings are often neutral in relatively short intervention studies.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: ((Research))
—
Liver Health
Human evidence for Liver Health has focused mainly on nonalcoholic fatty liver disease, and the overall pattern is mixed to neutral. Some individual trials report improvement in selected markers such as ALT or hepatic steatosis, but longer-term and pooled evidence has not shown a clear, consistent therapeutic effect across major NAFLD outcomes. ((Research)) ((Review))
Key human study
Dose studied: 1.5 g/day
Population: Overweight patients with histological NAFLD
Duration: 6 months
A placebo-controlled randomized clinical trial studied high-dose, long-term resveratrol in adults with histologically confirmed NAFLD. The trial did not find a consistent therapeutic effect on clinical or histologic endpoints, making it one of the more important neutral studies in this domain.
Result: Human clinical study reported no clear effect
Evidence strength: Moderate
Study source: ((Research))
Optional supporting context citation:
((Review))
—
Additional human study (if meaningful additional evidence exists)
Dose studied: 500 mg/day
Population: Patients with NAFLD
Duration: 12 weeks
A randomized, double-blind, placebo-controlled study in NAFLD reported no clear improvement in blood pressure, insulin resistance markers, or lipid profile. The study did report lower ALT and reduced hepatic steatosis, which illustrates why this domain is best described as mixed rather than uniformly negative.
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: ((Research))
—
Cognitive Health
Human research in Cognitive Health is smaller than the cardiometabolic literature but includes notable randomized trials in healthy aging and Alzheimer disease. Findings are mixed: one trial in healthy older adults reported memory-related improvement, while a longer phase 2 Alzheimer study mainly clarified exposure, cerebrospinal fluid penetration, safety, and biomarkers rather than establishing clear clinical benefit. ((Research)) ((Research))
Key human study
Dose studied: 200 mg/day
Population: Healthy overweight older adults
Duration: 26 weeks
A randomized trial in healthy older adults examined oral resveratrol for 26 weeks and measured memory outcomes alongside brain imaging markers. The study reported improved delayed retention memory and changes in hippocampal functional connectivity, making it one of the clearer positive cognitive signals in the human literature.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: ((Research))
—
Additional human study (if meaningful additional evidence exists)
Dose studied: 500 mg/day escalating to 1,000 mg twice daily
Population: Adults with mild to moderate Alzheimer disease
Duration: 52 weeks
A phase 2 randomized dose-escalation trial in Alzheimer disease tracked plasma and cerebrospinal fluid exposure, biomarkers, and tolerability during long-term administration. The study mainly informs pharmacokinetics, central nervous system penetration, and biomarker behavior rather than clear clinical efficacy, so its contribution is important but narrower than a positive outcome trial.
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: ((Research))
—
Obesity and Weight Regulation
Human evidence in Obesity and Weight Regulation is broader in pooled analyses than in clearly positive primary trials. Recent meta-analyses generally report no significant improvement in most metabolic or anthropometric outcomes in people with overweight or obesity, although isolated signals such as modest waist-circumference reduction have appeared in pooled analysis. ((Review)) ((Review))
Key human study
Dose studied: Resveratrol for 6 months; exact daily dose not clearly extractable from the locked source summary
Population: Overweight adults
Duration: 6 months
A randomized trial in overweight adults examined whether resveratrol improved insulin sensitivity over six months. The study did not show improved insulin sensitivity overall, although HbA1c was lower in the resveratrol arm, which fits the broader pattern of mixed metabolic findings rather than a consistent weight-regulation effect.
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: ((Research))
Optional supporting context citation:
((Review))
—
Additional human study (if meaningful additional evidence exists)
Dose studied: 1 g twice daily
Population: Obese men with metabolic syndrome
Duration: 30 days
A pilot randomized, placebo-controlled metabolic-unit trial tested high-dose resveratrol in obese men with metabolic syndrome. The study did not improve insulin resistance overall, although exploratory subgroup and microbiota findings were reported, making this best interpreted as small and exploratory rather than definitive obesity-focused evidence.
Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: ((Research))
Dosage & Study Snapshot (Research Context)
Human exposure studies of resveratrol range from small single-dose pharmacokinetic experiments to multi-month randomized trials using oral daily doses from 40 mg/day up to 2 g/day, with some higher single-dose PK work at 2.5 g. The literature is mainly intervention-based rather than dietary-intake-based in the locked library, and the lowest documented human exposure here comes from a niche pharmacokinetic study rather than from a core clinical efficacy domain. Across the clinical literature, studied exposures are highly heterogeneous and often broader than lower-dose commercial use patterns, while formulation and metabolism materially affect interpretation. ((Research)) ((Review))
25 mg single oral dose:
A small human pharmacokinetic study compared oral and intravenous administration in healthy volunteers. Oral absorption was reported as high, but unchanged circulating resveratrol remained low because the compound was rapidly metabolized into conjugated forms. This study is important because it helps explain why oral dose size does not translate directly into free plasma exposure. The work was a short PK study rather than an efficacy trial and mainly informs disposition, not clinical outcomes.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Very small healthy-volunteer PK study with no clinical outcome endpoint.
((Research))
40 mg/day:
This low daily dose was tested for 6 months in adults with type 2 diabetes in a randomized, double-blind, placebo-controlled trial. The study did not show clear improvement in CRP or broader metabolic outcomes at this exposure level. It is useful because it represents one of the lower repeated-dose regimens in the human intervention literature and provides a neutral comparison against higher-dose trials. The evidence here comes from a clinically relevant RCT, but the outcome pattern was negative overall.
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: Findings come from one diabetes population and may not generalize to other groups.
((Research))
75 mg/day:
A 12-week randomized, double-blind, placebo-controlled trial used this dose in nonobese postmenopausal women with normal glucose tolerance. Researchers measured liver, skeletal muscle, and adipose tissue insulin sensitivity and did not find improvement at this regimen. This study matters because it shows that lower-dose administration was not clearly effective even in a tightly phenotyped metabolic study. It also highlights that findings from diabetes trials do not automatically extend to metabolically healthier populations.
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: Population was relatively specific and not representative of all cardiometabolic-risk groups.
((Research))
80 mg single dose in enhanced oral formulation:
An enhanced micellar or hydrogel-style oral formulation was studied in healthy human subjects and compared with unformulated material. This formulation substantially increased unconjugated resveratrol exposure and changed Tmax and half-life relative to the comparator. The study is valuable because it shows that delivery technology can materially change measured exposure even when the nominal dose is not high. It informs absorption and formulation behavior more than clinical benefit.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Formulation-specific PK findings should not be generalized to all oral products.
((Research))
150 mg/day:
This daily dose appears in both cardiovascular and metabolic-syndrome trials and also matches the adult intake level assessed in an EFSA novel-food opinion for synthetic trans-resveratrol. In direct human trials, 150 mg/day did not clearly improve endothelial function over 4 weeks in overweight adults and did not improve major metabolic syndrome measures over 16 weeks in middle-aged men. This makes the dose important as both a research exposure and a regulatory context point, but the clinical findings at this level are largely neutral in the locked library. The EFSA opinion adds safety context under assessed use conditions but is not an efficacy source.
Result: Neutral overall findings
Evidence strength: Moderate
Notes / limitations: Regulatory safety context should not be read as proof of clinical benefit.
((Research)) ((EFSA))
200 mg/day for 26 weeks:
A randomized trial in healthy overweight older adults used this regimen in a cognitive-aging context. Researchers reported improved delayed retention memory and changes in hippocampal connectivity, making this one of the clearer positive human findings in the locked evidence set. The study stands out because it used a mid-range daily dose over a relatively long period and linked behavioral and imaging-related outcomes. Even so, it remains one trial in a narrower cognitive literature rather than a broadly replicated clinical program.
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: Positive cognitive findings have not been established as consistent across all populations or neurodegenerative conditions.
((Research))
500 mg/day:
This daily exposure appears in multiple clinical contexts. In adults with type 2 diabetes, 500 mg/day for 6 months did not clearly improve CRP or the broader metabolic pattern, while in NAFLD, 500 mg/day for 12 weeks did not improve blood pressure, insulin resistance markers, or lipids, although ALT and hepatic steatosis were reduced. This dose therefore illustrates the mixed-domain nature of the literature: some marker changes are reported, but consistent clinical benefit is not established. It is one of the most interpretable mid-to-upper daily doses because it recurs across more than one domain.
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Outcome patterns differ by population and endpoint.
((Research)) ((Research))
800 mg/day for 8 weeks:
This dose was tested in adults with type 2 diabetes in a randomized, double-blind, placebo-controlled trial. Blood glucose decreased, but inflammatory markers did not clearly improve. The regimen is notable because it produced a positive glycemic signal without a parallel broad anti-inflammatory signal in the same study. That split result is representative of the larger evidence base, where isolated favorable outcomes do not always extend across related endpoints.
Result: Modest improvement
Evidence strength: Moderate
Notes / limitations: Positive findings were short-term and limited to selected outcomes.
((Research))
1 g/day for 4 weeks:
A healthy-volunteer pharmacology study used this repeated daily dose to assess effects on cytochrome P450 enzyme activity. Researchers found modulation of CYP1A2, CYP2D6, CYP2C9, and CYP3A4 phenotypes, which is relevant to interaction risk rather than efficacy. This exposure level therefore matters mainly for interpretation of drug-metabolism effects in humans. It adds an important dimension to the literature because interaction potential can emerge even when efficacy remains uncertain.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This was a pharmacology interaction study in healthy volunteers, not a disease-outcome trial.
((Research))
1.5 g/day for 6 months:
A placebo-controlled randomized clinical trial used this high-dose regimen in overweight patients with histological NAFLD. The study did not find a consistent therapeutic effect on clinical or histologic endpoints. This is one of the more informative upper-range long-duration trials because it shows that higher dose and longer exposure did not automatically produce clearer benefit. One serious adverse event was also reported in the trial record.
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: High-dose neutral findings in NAFLD do not exclude smaller marker-level effects in other populations.
((Research))
2 g/day for 30 days:
A pilot randomized, placebo-controlled trial in obese men with metabolic syndrome used 1 g twice daily for one month. Overall insulin resistance did not improve, although exploratory subgroup and microbiota findings were described. This high-dose regimen is best viewed as exploratory because the trial was small and did not establish a clear overall metabolic benefit. It is useful mainly for understanding the upper range of direct administered exposures in short-term human research.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Small pilot trial with exploratory signals and limited generalizability.
((Research))
500 mg/day escalating to 1,000 mg twice daily over 52 weeks:
A phase 2 dose-escalation trial in adults with mild to moderate Alzheimer disease began at 500 mg/day and increased to 2 g/day over a year. The study showed measurable plasma and cerebrospinal fluid exposure and contributed valuable long-term tolerability and biomarker information. Its main value is pharmacokinetic and safety interpretation in a neurologic population rather than clear demonstration of cognitive efficacy. It also illustrates that central nervous system exposure has been studied under prolonged administration.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: The trial mainly informs exposure, biomarkers, and safety rather than confirmed clinical benefit.
((Research))
2.5 g single dose with 0, 5, or 25 mg piperine:
This single-dose PK pilot in healthy volunteers tested whether coadministration with piperine altered resveratrol pharmacokinetics. The study did not show a significant relationship between piperine dose and resveratrol PK values. This matters because piperine is often discussed as a bioavailability strategy, but the locked human evidence here does not show a clear advantage. The study is informative but small and formulation-specific.
Result: No clear effect
Evidence strength: Emerging
Notes / limitations: Single-dose pilot design limits conclusions about repeated use or clinical outcomes.
((Research))
Key Takeaways from Human Research
Ingredient Identity
Origin & Natural Occurrence
Resveratrol is a plant-produced polyphenol rather than a normal endogenous human compound. It is commonly associated with grapes and red wine, and the clinical literature more often studies purified oral resveratrol or trans-resveratrol preparations than ordinary food intake alone. ((Research)) ((EFSA))
In manufacturing and regulatory contexts covered by the locked library, synthetic trans-resveratrol is also relevant. The EFSA novel-food opinion specifically evaluated synthetic trans-resveratrol for adult use conditions, which means the regulatory evidence here includes both naturally occurring and manufactured forms. ((EFSA))
How It Behaves in the Body
Resveratrol behaves in the body as a compound that can be absorbed from the gut but is then rapidly transformed into other chemical forms. In plain language, that means a person may absorb the dose they swallow, yet only a relatively small amount of unchanged resveratrol may remain in circulation for long because the body quickly metabolizes it. This pharmacokinetic pattern is one of the main reasons human findings are hard to compare across studies. ((Research)) ((Review))
More technically, oral resveratrol undergoes extensive phase II metabolism, producing conjugated metabolites that dominate measured plasma exposure after dosing. Some human studies have also examined whether delivery systems can increase unconjugated exposure, and enhanced formulations have done so in controlled PK settings. This suggests that biological activity in humans may depend not only on dose but also on the balance between parent-compound exposure, metabolites, and formulation. ((Research)) ((Research))
Human pharmacology studies also suggest that repeated higher-dose administration can alter cytochrome P450 activity, including CYP1A2, CYP2D6, CYP2C9, and CYP3A4 phenotypes. In practical terms, that means resveratrol may affect how the body handles some other compounds at sufficiently high administered doses. What is well established is the rapid-metabolism and formulation-sensitive PK pattern; what remains less established is how strongly those PK differences translate into consistent clinical outcome differences across diseases. ((Research)) ((Review))
Absorption & Delivery Formats
Oral immediate-release: This is the dominant format in the locked human literature. Standard oral resveratrol shows absorption, but unchanged circulating resveratrol is often low because of rapid metabolism after dosing. ((Research))
Oral extended-release: Clear extended-release characterization is not established in the locked library. Available evidence is better for standard oral dosing and formulation-enhanced oral delivery than for a distinct extended-release clinical literature. ((Review))
Sublingual: Sublingual delivery is not clearly characterized in the locked library. Human evidence here appears absent or too limited to support a confident summary. ((Review))
Transdermal: Transdermal delivery is not characterized in the locked library’s accepted human evidence set. The locked sources support oral PK and oral intervention framing more clearly than non-oral delivery routes. ((Review))
Injectable / IV (research or clinical only): One early PK study included oral and IV comparison for pharmacokinetic interpretation, but this was a research tool rather than a standard clinical delivery program. The main value of the IV comparison was to help clarify absorption and metabolism rather than to support routine IV use. ((Research))
Quick Facts at a Glance
Onset (reported)
Reported onset is best characterized through pharmacokinetic exposure and short-term physiological measurements rather than through a single established clinical onset window. Single-dose studies show measurable exposure after oral dosing, and some crossover vascular trials assessed short-term postprandial responses, but a universal clinical onset time is not established across indications. ((Research)) ((Research))
Time to peak (Tmax)
Tmax has been studied in human PK work, and enhanced oral formulations can shift it relative to unformulated material. The locked library supports the general conclusion that Tmax is formulation-sensitive rather than fixed across all oral products. ((Research)) ((Review))
Half-life (t½)
An early human PK study reported a plasma half-life of about 9.2 hours for total resveratrol-related material rather than for unchanged free resveratrol alone. This distinction matters because circulating parent compound and conjugated metabolites do not behave identically. ((Research))
Typical duration
Human studies range from single-dose PK experiments to multi-month and one-year intervention trials. Repeated-dose efficacy trials commonly span 4 weeks to 6 months, while the Alzheimer disease phase 2 study extended to 52 weeks. ((Research)) ((Research))
Absorption routes studied
The locked evidence supports oral administration most strongly. There is also limited IV comparison in PK research, but clinical-use evidence remains overwhelmingly oral in the accepted library. ((Research))
Formulation differences
Formulation differences are clinically important for interpreting resveratrol research. Enhanced oral delivery systems can substantially increase unconjugated exposure, while piperine coadministration in one small pilot did not show a clear pharmacokinetic advantage. ((Research)) ((Research))
Variability drivers
Key variability drivers include dose, formulation, rapid metabolism, study duration, and the baseline health status of the population studied. These factors likely contribute to why positive findings in one setting are often not reproduced cleanly in others. ((Research)) ((Review))
Tolerance / adaptation (only if evidence exists)
Clear tolerance or adaptation patterns have not been firmly established in the locked library. Longer-term studies do show that resveratrol can be administered over months to a year, but the accepted sources do not establish a standard tolerance phenomenon analogous to loss of effect over time. ((Research))
Evidence strength snapshot
Pharmacokinetic evidence is more coherent than clinical efficacy evidence. Human outcome research is real and fairly broad, but it is heterogeneous, formulation-sensitive, and often mixed in pooled analysis. ((Review)) ((Review))
Other Physiological Contexts Studied (If Applicable)
Safety, Interactions & Regulation
Reported adverse effects in human studies include gastrointestinal symptoms such as nausea or diarrhea, along with headache, fatigue, and weight loss in some longer or higher-dose settings. Adverse-event reporting is not fully consistent across trials, which limits precision about frequency. ((Research)) ((Research))
Higher-dose clinical contexts deserve separate caution. In the Alzheimer disease dose-escalation trial, administration up to 1,000 mg twice daily was associated with gastrointestinal symptoms and weight loss. In a high-dose NAFLD trial at 1.5 g/day for 6 months, one serious adverse event involving fever and bicytopenia was reported. ((Research)) ((Research))
Human interaction evidence also exists. A healthy-volunteer study found that 1 g/day for 4 weeks changed phenotypic activity of CYP1A2, CYP2D6, CYP2C9, and CYP3A4, supporting real interaction potential at higher administered doses. ((Research)) EFSA likewise noted possible CYP2C9-related interaction concerns in its safety review of synthetic trans-resveratrol. ((EFSA))
In the U.S., resveratrol products may be marketed within the general dietary supplement framework, and FDA states that dietary supplements are regulated as foods rather than drugs. This is framework-level regulatory context and does not imply ingredient-specific FDA approval for resveratrol. ((FDA))
In the EU, the locked library includes an ingredient-specific EFSA novel-food opinion for synthetic trans-resveratrol. Under the assessed conditions of use, EFSA concluded that proposed adult intake up to 150 mg/day did not raise safety concerns, while also noting gastrointestinal symptoms at 1 g/day or higher. ((EFSA))
Evidence Overview
Human evidence for resveratrol is strongest in broad cardiometabolic research, more mixed in Liver Health and Cognitive Health, and limited by heterogeneity across dose, formulation, and population. The literature includes multiple randomized trials and several meta-analyses, but these do not converge on one consistently positive clinical pattern. Human trial evidence is more substantial than for many exploratory plant compounds, yet confidence is not higher because positive findings are uneven, often endpoint-specific, and frequently not reproduced across pooled analyses. ((Review)) ((Review)) ((Review))
Within Diabetes and Glycemic Control, randomized trials show conflicting results. One 8-week trial at 800 mg/day reported lower blood glucose, while a longer 6-month trial at 40 mg/day and 500 mg/day did not show broader metabolic improvement. Systematic review evidence therefore treats the diabetes literature as limited and not clearly practice-changing rather than uniformly favorable. ((Research)) ((Research)) ((Review))
Within Cardiovascular Health, direct randomized trials are often neutral, including endothelial-function and cardiometabolic risk-marker studies in overweight adults. Meta-analyses suggest that some vascular measures may improve in pooled analysis, but blood-pressure effects are not consistently demonstrated overall, and higher-dose subgroup findings have not resolved the larger inconsistency problem. This is a good example of pooled or subgroup-level signal not translating into a simple clinical conclusion. ((Research)) ((Research)) ((Review)) ((Review))
Within Liver Health, the NAFLD literature is also mixed. A 12-week trial at 500 mg/day reported lower ALT and hepatic steatosis, but a 6-month high-dose study at 1.5 g/day did not show consistent clinical or histologic benefit, and meta-analyses conclude that overall effects are negligible to small or not clearly useful for management. ((Research)) ((Research)) ((Review)) ((Review))
Within Cognitive Health, the evidence base is smaller and narrower than the cardiometabolic literature. One 26-week randomized trial in healthy older adults reported improved delayed retention memory, while a 52-week Alzheimer disease trial mainly contributed PK, biomarker, and safety data rather than clear efficacy. This means the translational rationale for cognitive interest is ahead of the clinical outcome evidence. ((Research)) ((Research))
Pharmacokinetic evidence adds important context. Oral resveratrol is rapidly metabolized, unchanged plasma levels are low after standard oral dosing, and enhanced formulations can substantially increase unconjugated exposure. These features likely contribute to differences among trials, along with variation in baseline metabolic status, study duration, and endpoint selection. Future confidence would be improved by larger replicated trials using clearly characterized formulations, better parent-versus-metabolite exposure reporting, and more consistent clinical endpoints within each domain. ((Research)) ((Research)) ((Review))
Evidence Confidence Classification
The overall human evidence base for resveratrol is Limited / Mixed because multiple human studies exist, but results are inconsistent across domains, doses, formulations, and populations. ((Review)) ((Review))
Interventional human evidence is substantial enough to show what has been tested, but results are often neutral or domain-specific rather than consistently positive. Observational and meta-analytic synthesis adds broader context but does not resolve the inconsistency seen in primary trials. Mechanistic and pharmacokinetic evidence is stronger than the clinical-outcome evidence in some respects, especially for absorption, metabolism, and formulation sensitivity. Regulatory context is available at the framework level in the U.S. and as an ingredient-specific EFSA safety opinion for synthetic trans-resveratrol in the EU, but these regulatory sources do not establish clinical efficacy. ((Review)) ((Review)) ((FDA)) ((EFSA))
Similar Ingredients & Comparators
Similar ingredients or related compounds:
Medical / pharma comparator categories:
Combination Context
Resveratrol + Piperine:
This combination was studied as a pharmacokinetic strategy to see whether piperine could increase resveratrol exposure in humans. In one small single-dose pilot, adding piperine did not show a significant pharmacokinetic advantage, so this remains a limited formulation-specific finding rather than an established enhancement approach. ((Research))
Resveratrol + EGCG:
A human combination trial in overweight and obese adults used 80 mg/day resveratrol with EGCG for 12 weeks and reported improved mitochondrial capacity and fat oxidation. This is combination-formulation evidence rather than standalone resveratrol evidence, so it should not be generalized to resveratrol alone. ((Research))
FAQ
What is this ingredient½
Resveratrol is a plant-derived polyphenol stilbene found naturally in foods such as grapes and red wine. In the human research literature, it is usually studied as an orally administered purified compound or trans-resveratrol preparation rather than only as a food exposure. ((Research)) ((EFSA))
What does human research study it for?
Human research studies resveratrol mainly for Diabetes and Glycemic Control, Cardiovascular Health, Liver Health, and Cognitive Health. The broadest direct-use literature is cardiometabolic, while cognitive studies are fewer and more specialized. ((Review)) ((Review))
What are the best-supported uses?
The best-supported human research areas are cardiometabolic and liver-related questions, mainly because these have the most repeated trials and meta-analyses. Even in these domains, however, the evidence is mixed rather than clearly confirmatory, so �gbest-supported�h here means most studied, not most conclusively established. ((Review)) ((Review))
Where is evidence mixed or limited?
Evidence is mixed in type 2 diabetes, cardiovascular risk markers, NAFLD, and obesity-related outcomes because individual trials and pooled analyses do not show a uniform pattern of benefit. Cognitive evidence is also limited by smaller study volume and by the fact that positive aging-related findings have not yet translated into clearly established efficacy in Alzheimer disease trials. ((Research)) ((Review)) ((Research))
How quickly does it act (onset)?
Resveratrol has a measurable pharmacokinetic onset after oral dosing, but a single universal clinical onset time is not established across conditions. The locked library supports early absorption and measurable exposure in PK studies, while longer-term clinical studies often run for weeks to months before assessing outcomes. ((Research)) ((Research))
What affects absorption and variability?
Absorption and variability are affected by rapid metabolism, formulation differences, dose, and the health status of the population being studied. Enhanced oral formulations can increase unconjugated exposure, while standard oral forms often yield low circulating unchanged resveratrol despite absorption. ((Research)) ((Research))
Is tolerance reported?
A clear tolerance pattern has not been established in the locked human evidence. Longer trials show that repeated administration over months to a year is feasible in research settings, but the accepted sources do not define a standard loss-of-effect phenomenon over time. ((Research))
Why do studies disagree?
Studies disagree mainly because they use different doses, formulations, durations, endpoints, and populations. Another major reason is pharmacokinetics: resveratrol is rapidly metabolized, so nominal dose does not reliably predict unchanged systemic exposure across studies. ((Review)) ((Research))
What ingredients is it commonly combined with and why?
In the locked human evidence, resveratrol has been combined with piperine to test whether exposure could be increased and with EGCG in a metabolic combination study. Piperine did not show a clear PK advantage in the small pilot study, while the EGCG trial was a combination-formulation study that cannot be interpreted as standalone resveratrol evidence. ((Research)) ((Research))
What foods naturally contain this ingredient½
Resveratrol naturally occurs in grapes and red wine, which is why it is often described as a food-derived polyphenol. However, the accepted human clinical literature is much stronger for administered purified forms than for controlled studies of ordinary dietary intake. ((Research))
How is it regulated?
In the U.S., resveratrol products may be marketed under the general dietary supplement framework, and FDA states that dietary supplements are regulated as foods rather than drugs. In the EU, the locked library includes an EFSA novel-food safety opinion for synthetic trans-resveratrol under assessed adult use conditions up to 150 mg/day, which is a safety opinion rather than proof of efficacy. ((FDA)) ((EFSA))
